Telesta Therapeutics Provides Key Corporate UpdatesPR Newswire Telesta Therapeutics Inc. 6 minutes ago MONTREAL, April 27, 2015 /PRNewswire/ - Telesta Therapeutics Inc. (TSX:TST; PNK:BNHLF) provided the following key corporate updates: •Submission of Biologics Licensing Application (BLA) to the United States Food and Drug Administration (FDA) for marketing approval of MCNA1 remains targeted for June 30, 2015; •Negotiations for the partnering of MCNA are ongoing; •Presentations scheduled at two upcoming investor forums; •Equity coverage initiated by two investment banks; Telesta Therapeutics announced today that it is continuing to target the submission of a Biologics License Application (BLA) to the United States Food and Drug Administration (FDA) for the marketing approval of MCNA by June 30th. Commenting on this update, Dr. Michael Berendt, CEO and Chief Scientist noted: "My clinical, regulatory, quality and manufacturing teams are working hard and we remain committed to submitting our BLA before the end of the second calendar quarter. As we approach this key value inflection point, it is critical that we do everything we can to file the highest quality BLA possible to ensure that we are able to deliver a new and much needed therapeutic option for bladder cancer patients that have not seen a new drug approved since 1998!" The Company also reported that there continues to be significant 3rd party interest in the MCNA program and that it is seriously evaluating partnering opportunities and actively negotiating multiple non-binding expressions of interest from a number of public and private pharmaceutical and biotechnology companies who are attracted to MCNA's late stage specialty product profile, therapeutic area and market potential. Due to the confidential nature of the ongoing discussions, Telesta will only provide further updates to shareholders on execution of a binding agreement. Telesta also announced today that they are continuing to work with Bristol Capital, an internationally focused Investor Relations firm, to organize an ongoing program of investor meetings in key North American financial centers. Telesta will be presenting at two upcoming institutional investors forums: the 2015 Bloom Burton Healthcare Investor Conference in Toronto, Ontario as well as the LD Micro-Invitational Investor Conference in Los Angeles, California; details of both conferences can be found on Telesta's website at www.telestatherapeutics.com. In addition, initial equity coverage of Telesta Therapeutics has recently been initiated by Euro Pacific Canada (March 4, 2015) and M Partners (April 22, 2015) and the company remains in discussions with other North American financial institutions concerning the possibility of adding to this coverage in the months to come.